United Therapeutics Corporation — Cyborg Score 8/10
Strong
Biotechnology & Specialty Pharmaceuticals
Strategic Profile
Many of the company's products are focused towards lung disease and organ manufacturing. Key approved products include Orenitram, Remodulin, Tyvaso, and Tyvaso DPI for pulmonary arterial hypertension, with Tyvaso and Tyvaso DPI also indicated for pulmonary hypertension associated with interstitial lung disease. The pipeline includes gene therapy products like Aurora-GT and development-stage xenografts for organ replacement.
Cyborg Score Rationale
United Therapeutics has a market cap of approximately $22.9 billion with a P/E ratio of 19.15. The company combines strong commercial products in rare respiratory diseases with pioneering work in xenotransplantation technology, providing differentiated growth drivers and addressing critical unmet medical needs.
Top Insights
Pioneering xenotransplantation leader with recent successful porcine heart and kidney transplants demonstrating clinical feasibility of organ replacement solutions
Established commercial platform with $2.8B+ annual revenue generated from four FDA-approved products for pulmonary hypertension treatment
Strategic M&A activity (Miromatrix, IVIVA, Revivicor acquisitions) builds bioengineering and organ manufacturing capabilities
First publicly-traded pharma company structured as a public benefit corporation, embedding stakeholder value beyond shareholders
Named Competitors
Pulmonary Hypertension Therapies — Competing PAH treatments including ambrisentan
Revatio — Sildenafil for pulmonary arterial hypertension
Adcirca (tadalafil) — Competing PAH therapy; partially licensed by UTHR
Organ Transplant Technologies — Bioengineered organ development; now acquired by UTHR
Recent Developments
(2024) First successful transplant of xenokidney with ten gene edits; 500th lung transplant using UT's EVLP service
(2023) Completed acquisition of Miromatrix Medical for bioengineered organs; FDA approved Tyvaso DPI for PAH and PH-ILD
(2023) First successful xenotransplantation of porcine heart transplant
(2023) Acquired IVIVA Medical Inc. for $50 million
Open the full interactive United Therapeutics Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.